Tesamorelin
Tesamorelin Acetate (TH9507)
Get Tesamorelin
Sourced from Ascension Peptides. Verified ≥≥99% purity, third-party tested. COA included.
Off with code
PEPTIDEDECK
Table of Contents
What is Tesamorelin?
Tesamorelin is a growth hormone-releasing hormone analog, a synthetic peptide that mimics the natural hypothalamic hormone responsible for signaling the pituitary gland to make and secrete growth hormone. By stimulating the body's own growth hormone production rather than replacing it, tesamorelin represents a physiological alternative to direct growth hormone administration.
Tesamorelin is built on the complete 44 amino acid sequence of native GHRH, distinguishing it from shorter GHRH-based peptides that use only the active fragment. To this full sequence it adds a trans-3-hexenoic acid group at the N-terminus. Native GHRH is degraded within minutes by the enzyme dipeptidyl peptidase-4, and this modification protects the peptide from that breakdown, giving tesamorelin a longer and more useful duration of action while preserving full activity at the GHRH receptor.
The rationale for tesamorelin in HIV-associated lipodystrophy is specific: this condition involves an abnormal accumulation of visceral fat, and growth hormone strongly promotes the breakdown of that deep abdominal fat. By raising the body's growth hormone in a controlled, pulsatile way, tesamorelin reduces visceral fat while preserving the natural regulation that would be lost with direct growth hormone dosing. Beyond this approved use, tesamorelin's ability to mobilize fat, including fat stored in the liver, has driven research into fatty liver disease and metabolic health.
Research Benefits
FDA-approved for reducing visceral adipose tissue
Stimulates natural pulsatile growth hormone release
Preserves hypothalamic-pituitary feedback regulation
Improves trunk fat and waist circumference
May reduce liver fat in NAFLD
Potential cognitive benefits in aging populations
Favorable lipid profile effects
Does not significantly impair glucose metabolism
How Tesamorelin Works
Tesamorelin works by binding to the growth hormone-releasing hormone receptor on somatotroph cells in the anterior pituitary gland, triggering the synthesis and release of growth hormone. This is the same receptor and the same signaling used by the body's own GHRH, which is why tesamorelin reproduces natural growth hormone physiology rather than overriding it.
GHRH Receptor Signaling
Tesamorelin activates the GHRH receptor, a G-protein coupled receptor that stimulates the enzyme adenylyl cyclase and raises intracellular cyclic AMP. The rise in cyclic AMP activates protein kinase A, which drives both the immediate release of stored growth hormone and increased production of new growth hormone. The released growth hormone then acts on the liver and other tissues, raising insulin-like growth factor 1, the mediator of many of growth hormone's downstream effects.
GHRH Receptor Agonism
Binds pituitary GHRH receptors to stimulate natural growth hormone synthesis and release.
Pulsatile GH Release
Preserves the natural rhythmic pattern of growth hormone secretion rather than a constant level.
Visceral Fat Reduction
Growth hormone promotes breakdown of deep abdominal fat, the target of the approved use.
Feedback Regulation
Maintains normal hypothalamic-pituitary feedback, limiting excessive growth hormone levels.
Preserving Pulsatility
Tesamorelin's central advantage over direct growth hormone injection is that it preserves the body's pulsatile secretion pattern. Growth hormone is naturally released in bursts, and this rhythm appears important for its physiological effects and for maintaining tissue sensitivity. Because tesamorelin acts one step upstream, at the pituitary, the resulting growth hormone still passes through normal feedback controls, so the body can restrain output if levels rise too high. This reduces the risk of the sustained, unregulated growth hormone exposure that can accompany direct dosing.
Effects on Fat, Including the Liver
Tesamorelin's most clinically useful action is mobilizing fat. Growth hormone is a potent lipolytic hormone, meaning it promotes the breakdown of stored triglycerides, with a pronounced effect on visceral abdominal fat. This same fat-mobilizing action extends to the liver, where reducing fat content is the basis for tesamorelin's investigation in non-alcoholic fatty liver disease. The effect on visceral and hepatic fat, achieved without the muscle-wasting seen in some conditions, is what makes tesamorelin distinctive among growth hormone therapies.
Research Applications
HIV-associated lipodystrophy (FDA-approved)
Active research area with published studies
Non-alcoholic fatty liver disease (NAFLD)
Active research area with published studies
Cognitive function in aging and HIV
Active research area with published studies
Visceral obesity and metabolic syndrome
Active research area with published studies
Body composition optimization
Active research area with published studies
Cardiovascular risk markers
Active research area with published studies
Age-related GH decline
Active research area with published studies
Liver enzyme improvement
Active research area with published studies
Research Findings
Tesamorelin is supported by clinical trials that led to its approval for HIV-associated lipodystrophy and by an expanding body of research into fatty liver disease and cognitive function. The findings consistently show meaningful reductions in visceral and hepatic fat.
Visceral Fat Reduction
Tesamorelin's pivotal trials in people with HIV-associated lipodystrophy demonstrated significant reductions in visceral adipose tissue, the deep abdominal fat associated with metabolic and cardiovascular risk. Treatment reduced trunk fat and waist circumference while raising insulin-like growth factor 1, and the visceral fat reduction was accompanied by favorable changes in some lipid measures. These results formed the basis for tesamorelin's approval.
🔑 Key Clinical Findings
- Tesamorelin significantly reduces visceral abdominal fat in HIV-associated lipodystrophy
- It raises insulin-like growth factor 1 while preserving pulsatile growth hormone secretion
- Research shows reductions in liver fat, supporting study in non-alcoholic fatty liver disease
- It does not substantially worsen glucose control at approved doses in studied populations
- Cognitive research explores potential benefits in aging and in people with HIV
Liver Fat and Metabolic Research
Tesamorelin has been studied for its effect on liver fat in people with HIV and hepatic steatosis, with research showing reductions in the fat accumulated within the liver. Because excess liver fat drives progression toward inflammation and fibrosis, a therapy that mobilizes hepatic fat is of considerable interest. This research extends tesamorelin's mechanism beyond its approved abdominal-fat indication into the broader field of metabolic liver disease.
| Compound | Structure | Half-Life | Approval Status |
|---|---|---|---|
| Native GHRH | 44 amino acids | ~7 minutes | Not a drug |
| Sermorelin | GHRH 1-29 fragment | 10-20 minutes | Historically available |
| Tesamorelin | Full 44 aa, stabilized | 26-38 minutes | FDA-approved |
Cognitive Research
Tesamorelin has been examined for effects on cognition, based on the observation that the growth hormone and insulin-like growth factor 1 axis influences brain function. Studies in aging adults and in people with HIV have explored measures of memory and executive function. This line of research is earlier stage than the metabolic work, but it reflects growing interest in how modulating growth hormone signaling might support cognitive health.
Dosage & Administration
Tesamorelin is a prescription medication, and the dosing and reconstitution information below describes clinical use for context, not as personal medical instruction. Any use of tesamorelin should be prescribed and supervised by a qualified healthcare provider.
Formulation and Route
Tesamorelin is supplied as a lyophilized (freeze-dried) powder that must be reconstituted with sterile water before injection. It is given by subcutaneous injection once daily, typically into the abdomen, with rotation of the injection site. The short circulating half-life of roughly 26 to 38 minutes is sufficient because the goal is to trigger a pulse of natural growth hormone release rather than to maintain a constant drug level.
Reconstitution
Gather Materials
Obtain the powder vial, the supplied sterile water, alcohol swabs, and an appropriate syringe.
Add Diluent Gently
Introduce the sterile water slowly against the vial wall rather than directly onto the powder.
Dissolve Without Shaking
Swirl gently to dissolve; avoid vigorous shaking, which can damage the peptide.
Inject Promptly
The reconstituted solution is drawn up and injected soon after preparation, following product instructions.
Dosing Approach
| Parameter | Approach | Rationale |
|---|---|---|
| Frequency | Once daily | Reproduces a daily growth hormone pulse |
| Timing | Consistent daily time | Maintains a steady rhythm of stimulation |
| Site | Abdomen, rotated | Reduces local injection reactions |
Practical Insight
Consistency matters with tesamorelin. Because its benefit builds over months of daily pulsatile stimulation, adherence to the daily schedule is central to achieving and maintaining reductions in visceral and liver fat.
Work out your Tesamorelin draw in units
Enter the vial size, the bacteriostatic water you add and the dose you want, and the calculator gives the syringe units, how long the vial lasts and when to discard it.
Open the peptide calculatorSafety & Side Effects
Tesamorelin has a defined safety profile from its clinical program and approved use. Because it raises growth hormone and insulin-like growth factor 1, its side effects and cautions largely reflect the effects of those hormones.
Common Side Effects
Tesamorelin most frequently causes injection site reactions and effects related to elevated growth hormone.
Injection Site Reactions
Redness, itching, pain, or irritation at the injection site, the most common effect.
Joint Pain and Swelling
Arthralgia and fluid retention can occur, consistent with elevated growth hormone.
Edema
Mild swelling from fluid retention, a recognized growth hormone effect.
Muscle Aches
Myalgia and general aches are reported by some users, usually mild.
Important Safety Considerations
Tesamorelin carries considerations tied to raising growth hormone and to specific contraindications:
- Glucose regulation: Growth hormone has anti-insulin effects, so glucose is monitored, particularly in people with or at risk of diabetes
- Active malignancy: Because growth hormone and insulin-like growth factor 1 can promote cell growth, tesamorelin is contraindicated in active cancer
- Pituitary conditions: It is not appropriate in people with disruption of the pituitary axis from tumor, surgery, radiation, or head trauma
- Pregnancy: Tesamorelin is not used during pregnancy, as reducing maternal fat mass offers no benefit and growth hormone effects are a concern
- Hypersensitivity: Allergic reactions can occur and warrant discontinuation
Monitoring
Tesamorelin therapy includes monitoring of insulin-like growth factor 1 to guide response and safety, periodic assessment of blood glucose, and evaluation for fluid retention or joint symptoms. Because the benefit is reassessed over time, treatment is continued only while it produces meaningful reduction in the targeted fat and is well tolerated.